TerminatedNot Applicable

Effect of Hyperandrogenism on IVF Outcomes in PCOS Patients

Stopped: Low recruitment rate

Canada32 participantsStarted 2022-01-21

Plain-language summary

Ovulatory dysfunction affects 18 to 25% of infertile women, the most common identifiable condition is polycystic ovarian syndrome (PCOS). The most frequent symptoms of PCOS are oligo-anovulation, hyperandrogenism and polycystic ovary appearance. Hyperandrogenism is the main contributor that affects oocyte and embryo quality and decreases the success rates in PCOS patients undergoing IVF treatments. The aim of this study is to determine the effect of hyperandrogenism as an independent factor on IVF success rates and oocyte/embryo quality in PCOS patients undergoing IVF.

Who can participate

Age range18 Years – 39 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women between ages of 18 - 39 inclusively * ≥15 oocytes collected on the day of oocyte retrieval and/or anti-mullerian hormone (AMH) ≥ 4.0 ng/ml in the participant's medical chart in the last 24 months Exclusion Criteria: * Male factor necessitating testicular sperm aspiration (TESA), testicular sperm extraction (TESE) or micro-TESE * Fertility preservation * Recurrent pregnancy losses (RPL) (defined as 2 or more failed clinical pregnancies as documented by ultrasonography or histopathologic examination,or 3 or more failed pregnancies before 14 weeks of gestation) * Oocyte donation * Medical diagnosis of non classic congenital adrenal hyperplasia diagnosed based on 17 hydroxyprogesterone level

What they're measuring

Evaluate the effect of hyperandrogenism on frozen embryo transfer

Timeframe: 10 days after frozen embryo transfer

Trial details

NCT IDNCT05555680

SponsorClinique Ovo

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-01-29